Cancer
FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi
November 27, 2018Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma
The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
Immuno Biotech owner promoting unlicensed ‘cure’ for cancer, autism and HIV to be sentenced next week
November 23, 2018Medical Communications Cancer, David Noakes, GcMAF, HIV, UKIP, autism
The owner of Guernsey-based biotech Immuno Biotech Ltd, David Noakes, will be sentenced this week after admitting to a number …
Cancer Drugs Fund to offer MSD’s Keytruda for lung cancer
November 22, 2018Sales and Marketing CDF, Cancer, Cancer Drugs Fund, NHS, NICE, UK, keytruda, pharma
MSD’s Keytruda (pembrolizumab) will now be made available via the Cancer Drugs Fund for patients in England, as NICE announces …
Merck KGaA and Pfizer’s Bavencio falls short in ovarian cancer
November 20, 2018Manufacturing and Production, Research and Development Bavencio, Cancer, Merck MGaA, Pfizer, ovarian cancer, pharma
Merck KGaA and Pfizer’s Bavencio (avelumab) has missed its primary endpoints in the treatment of platinum-resistant or -refractory ovarian cancer, …
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
November 19, 2018Sales and Marketing Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with …
AstraZeneca’s Imfinzi immunotherapy combo fails to show benefit in lung cancer
November 16, 2018Medical Communications, Research and Development AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca has revealed that its immunotherapy combo of Imfinzi (durvalumab) and tremelimumab failed to meet its primary endpoint in a …
Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment
November 16, 2018Medical Communications Boehringer, Cancer, Epizyme, deal, oncology
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …
Kymriah to be made available in UK for paediatric leukaemia patients via Cancer Drugs Fund
November 15, 2018Sales and Marketing CAR-T, Cancer, Cancer Drugs Fund, Kymriah, NHS, NICE, leukaemia, pharma
NICE has announced its recommendation that Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) be made available in the treatment of relapsed …
MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer
November 15, 2018Research and Development Cancer, MSD, PD-L1, keytruda, pharma
MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …
Azacitidine and nivolumab combo proves successful in phase II trial
November 13, 2018Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas
A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …
MSD’s Keytruda chalks up FDA approval in liver cancer
November 12, 2018Sales and Marketing Cancer, FDA, US, hepatocellular carcinoma, keytruda, pharma
MSD’s blockbuster immunotherapy Keytruda has secured another FDA approval, this time for the treatment of hepatocellular carcinoma (HCC) in patients …
Working Life: Philippe Bastide, Head of Biosimilars, Mundipharma
November 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Mundipharma, Philippe Bastide, biosimilars, leukaemia
“Don’t conform to what people want – take risks. The people who make a big difference are the ones who …
Eisai’s Lenvima wins over NICE in liver cancer in just three months
November 9, 2018Medical Communications, Sales and Marketing Cancer, Eisai, Lenvima, Levantinib, NHS, NICE, UK, liver cancer, pharma
Eisai has revealed that its multireceptor Tyrosine Kinase Inhibitor Lenvima (lenvatinib) has been recommended by NICE, meaning it can now …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
Prostate cancer researchers win $2m to explore carboplatin therapy
November 7, 2018Research and Development Cancer, carboplatin therapy, prostate cancer
The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …
Latest content
Five Facts about cardiovascular disease
